Tumor-targeting monoclonal antibodies to FZD10 and uses thereof
The present invention relates to an antibody or a fragment thereof which is capable of binding to a Frizzled homologue 10 (FZD10) protein, such as a mouse monoclonal antibody, a chimeric antibody and a humanized antibody. Also, the present invention relates to a method for treating and/or preventing FZD10-associated disease; a method for diagnosis or prognosis of FZD10-associated disease; and a method for in vivo imaging of FZD10 in a subject.
1. A method for treating a disease associated with Frizzled homologue 10 (FZD 10), comprising administering to a patient in need thereof an antibody or fragment thereof and a pharmaceutically acceptable carrier or excipient, wherein the disease associated with FZD 10 is synovial sarcoma, and wherein the antibody or fragment is selected from:
(i) an antibody or fragment thereof, which comprises an H (heavy) chain V (variable) region comprising a complementarity determining region (CDR) having the amino acid sequences shown in SEQ ID NOs: 15, 17 and 19 and an L (light) chain V region comprising a CDR having the amino acid sequences shown in SEQ ID NOs: 23, 25 and 27, and which is capable of binding to a Frizzled homologue 10 (FZD10) protein or a partial peptide thereof; or
(ii) an antibody or fragment thereof, which binds the FZD10 protein and in which the complementarity determining regions (CDRs) are the CDRs of the mouse monoclonal antibody 92-13 (FERM BP-10628).
2. The method according to claim 1 , wherein the antibody is selected from the group consisting of a mouse antibody, a chimeric antibody, a humanized antibody, an antibody fragment, and single-chain antibody.
3. The method according to claim 1 , wherein the antibody is a mouse antibody.
4. The method according to claim 3 , wherein the mouse antibody comprises an H chain having the amino acid sequence shown in SEQ ID NO: 57 and/or an L chain having the amino acid sequence shown in SEQ ID NO: 59.
5. The method according to claim 3 , wherein the mouse antibody is produced by the hybridoma clone 92-13 (FERM BP-10628).
6. The method according to claim 1 , wherein the antibody is a chimeric antibody.
7. The method according to claim 6 , wherein the chimeric antibody comprises an H chain V region having the amino acid sequence shown in SEQ ID NO: 13.
8. The method according to claim 6 , wherein the chimeric antibody comprises an H chain having the amino acid sequence shown in SEQ ID NO: 46.
9. The method according to claim 6 , wherein the chimeric antibody comprises an L chain V region having the amino acid sequence shown in SEQ ID NO: 21.
10. The method according to claim 6 , wherein the chimeric antibody comprises an L chain having the amino acid sequence shown in SEQ ID NO: 48.
11. The method according to claim 6 , wherein the chimeric antibody comprises an H chain V region having the amino acid sequence shown in SEQ ID NO: 13 and an L chain V region having the amino acid sequence shown in SEQ ID NO: 21.
12. The method according to claim 6 , wherein the chimeric antibody comprises an H chain having the amino acid sequence shown in SEQ ID NO: 46 and an L chain having the amino acid sequence shown in SEQ ID NO: 48.
13. The method according to a claim 6 , wherein the chimeric antibody further comprises a human antibody C (constant) region.
14. The method according to claim 1 , wherein the antibody is a humanized antibody.
15. The method according to claim 14 , wherein the humanized antibody further comprises a human antibody FR (framework) region and/or a human antibody C region.
16. The method according to claim 1 , wherein the antibody is a chimeric antibody that further comprises a human antibody C (constant) region or which is a humanized antibody that further comprises a human antibody FR (framework) region and/or a human antibody C region.
17. The method according to claim 1 , wherein the antibody is a chimeric antibody comprising:
(i) an H chain V region having the amino acid sequence shown in SEQ ID NO: 13 and an L chain V region having the amino acid sequence shown in SEQ ID NO: 21; or
(ii) an H chain having the amino acid sequence shown in SEQ ID NO: 46 and an L chain having the amino acid sequence shown in SEQ ID NO: 48.
18. The method according to claim 1 , wherein the antibody or fragment thereof is labeled with a radioisotope label or a fluorescent label.
19. The method according to claim 18 , wherein the radioisotope label is selected from the group consisting of 90 yttrium ( 90 Y), 125 iodine ( 125 I), and 111 indium ( 111 In).